Genomic aberrations may be associated with both PFS and OS. (A-B) Gain in 2p (encompassing VRK2, FANCL, and LINC01122); (C-D) gain in 1q (H3F3A); and (E-F) deletion in 17p (TP53). Patients were grouped based on the presence (red) or absence (blue) of the aberration. Kaplan-Meier analysis was performed to investigate the association between the aberration and clinical outcome, including PFS (A,C,E) and OS (B,D,F). N.S., not significant.